Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context

Enfortumab vedotin (EV) is a novel antibody–drug conjugate that is the first in class to be FDA-approved for use in patients with treatment-refractory urothelial cancer. Enfortumab is comprised of an antibody targeting nectin-4, widely expressed in urothelial cancers, with an monomethyl auristatin E...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman-Censits, Jean, Maldonado, Laneisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762760/
https://www.ncbi.nlm.nih.gov/pubmed/36545447
http://dx.doi.org/10.2147/OTT.S370900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762760/
https://www.ncbi.nlm.nih.gov/pubmed/36545447
http://dx.doi.org/10.2147/OTT.S370900

Ejemplares similares